Home

GlucoTrack, Inc. - Common Stock (GCTK)

0.6641
-0.0459 (-6.46%)

GlucoTrack, Inc. is a healthcare technology company focused on the development of innovative non-invasive glucose monitoring solutions for individuals with diabetes

The company leverages advanced sensing technologies to create devices that enable users to track their blood glucose levels without the need for traditional fingerstick methods. GlucoTrack aims to improve the quality of life for diabetic patients by providing them with more convenient and accessible ways to manage their condition, while also enabling healthcare providers to better monitor patient health. Through its commitment to research and development, GlucoTrack seeks to contribute to more effective diabetes management and enhance overall patient outcomes.

SummaryNewsPress ReleasesChartHistoricalFAQ
Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor
The study met its primary endpoint with no procedure or device related serious adverse events reported
By Glucotrack, Inc. · Via GlobeNewswire · February 4, 2025
Glucotrack Announces Reverse Stock Split
1-for-20 reverse stock split to become effective as of the opening of trading on February 4, 2025
By Glucotrack, Inc. · Via GlobeNewswire · January 30, 2025
Glucotrack Strengthens Leadership Team with Appointment of New Chief Financial Officer
Industry veteran Peter C. Wulff joins Glucotrack to drive financial strategy and commercialization of its continuous blood glucose monitor for people with diabetes
By Glucotrack, Inc. · Via GlobeNewswire · January 29, 2025
Glucotrack Announces ISO 13485:2016 Certification
ISO Certification highlights commitment to quality for continuous blood glucose monitor
By Glucotrack, Inc. · Via GlobeNewswire · January 21, 2025
Glucotrack Strenghtens Leadership Team with Addition of Industry Veteran as Vice President of Regulatory Affairs
New hire set to drive clinical development and U.S. commercialization of the continuous blood glucose monitor for people with diabetes
By Glucotrack, Inc. · Via GlobeNewswire · January 15, 2025
Glucotrack to Present at TechBio Showcase™ 2025
Presentation to feature an update on the Company’s novel continuous blood glucose monitor for patients with diabetes
By Glucotrack, Inc. · Via GlobeNewswire · January 7, 2025
The Power Play by The Market Herald Releases New Interviews with GlucoTrack and Acceleware Discussing Their Latest News
VANCOUVER, BC / ACCESSWIRE / July 26, 2023 / The Power Play by The Market Herald has announced the release of new interviews with GlucoTrack and Acceleware discussing their latest news.
Via ACCESSWIRE · July 26, 2023
Aegis Capital Corp. Acted as Sole Bookrunner on a $10 Million Underwritten Public Offering for GlucoTrack, Inc. (NASDAQ: GCTK)
NEW YORK, NY / ACCESSWIRE / April 17, 2023 / Aegis Capital Corp. acted as Sole Bookrunner on a $10 Million Underwritten Public Offering for GlucoTrack, Inc. (NASDAQGCTK).
Via ACCESSWIRE · April 17, 2023
The Power Play by The Market Herald Releases New Interviews with NextSource, Good Natured Products, SoLVBL, Geologica and GlucoTrack Discussing Their Latest News
VANCOUVER, BC / ACCESSWIRE / October 27, 2022 / The Power Play by The Market Herald has announced the release of new interviews with NextSource, Good Natured Products, SoLVBL, Geologica and GlucoTrack discussing their latest news.
Via ACCESSWIRE · October 27, 2022
GLUCOTRACK ANNOUNCES THE HIRING OF DR. MARK TAPSAK
INDUSTRY VETERAN TO LEAD NEW CONTINUOUS GLUCOSE MONITORING R&D PROGRAM
By GlucoTrack, Inc. · Via GlobeNewswire · October 14, 2022
The Power Play by The Market Herald Releases New Interviews with SoLVBL, C3 Metals, Charbone Hydrogen, GlucoTrack and Atomic Minerals Discussing Their Latest News
VANCOUVER, BC / ACCESSWIRE / October 12, 2022 / The Power Play by The Market Herald has announced the release of new interviews with SoLVBL, C3 Metals, Charbone Hydrogen, GlucoTrack and Atomic Minerals discussing their latest news.
Via ACCESSWIRE · October 12, 2022
GLUCOTRACK TO BEGIN RESEARCH & DEVELOPMENT OF NOVEL CONTINUOUS GLUCOSE MONITORING SYSTEM
Rutherford, NJ, Oct. 10, 2022 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a non-invasive device and digital health platform for measuring glucose levels in people with Type 2 diabetes and prediabetes, announced today it is expanding its product pipeline with the commencement of a new R&D program for a long-term continuous glucose monitor.
By GlucoTrack, Inc. · Via GlobeNewswire · October 10, 2022